Abstract
This study was designed to evaluate the efficacy and safety of XELOX plus bevacizumab in a Japanese metastatic colorectal cancer population that included elderly patients. This was a multicenter, single-arm, open-label prospective study. The major inclusion criteria were previously untreated metastatic colorectal cancer, presence of measurable lesions, age ≥ 20 years; Eastern Cooperative Oncology Group performance status of 0-2, and adequate organ function. Patients received bevacizumab (7.5 mg/kg on day 1) and XELOX (130 mg/m(2) oxaliplatin on day 1 plus 1,000 mg/m(2) capecitabine b.i.d. on days 1-14) every 3 weeks. The primary endpoint was confirmed objective response rate. The study included 47 patients (male/female 30/17; median age 69 years; age range 38-81 years with 10 patients ≥ 75 years; PS 0/1/2, 40/5/2) enrolled between May 2010 and March 2011. Responses were assessed in 46 eligible patients. The objective response rate was 52.2 % (95 % confidence interval [CI] 37.0-67.1). The median progression-free survival and overall survival were 10.0 months (95 % CI 7.8-12.3) and 34.6 months (95 % CI 19.9-not estimable), respectively. Frequently encountered grade 3 and 4 adverse events in this study were aspartate aminotransfer...Continue Reading
References
Aug 16, 2000·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·A de GramontA Bonetti
Sep 28, 2000·The New England Journal of Medicine·L B SaltzL L Miller
Apr 17, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·P M HoffR Wong
Nov 2, 2001·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·E Van CutsemUNKNOWN Xeloda Colorectal Cancer Study Group
Sep 1, 2006·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Richard M GoldbergDaniel J Sargent
May 2, 2007·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Eric Van CutsemRafael G Amado
Nov 16, 2007·The New England Journal of Medicine·Derek J JonkerMalcolm J Moore
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Jim CassidyLeonard Saltz
Apr 19, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Leonard B SaltzJim Cassidy
Jul 22, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Howard S HochsterEric Hedrick
Dec 10, 2008·Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology·Fairooz F KabbinavarOliver Rosen
Dec 30, 2008·Critical Reviews in Oncology/hematology·Javier SastreEduardo Díaz-Rubio
Feb 7, 2009·The New England Journal of Medicine·Jolien TolCornelis J A Punt
May 14, 2010·Japanese Journal of Clinical Oncology·Toshihiko DoiHiroya Takiuchi
May 18, 2010·International Journal of Cancer. Journal International Du Cancer·Michel DucreuxUNKNOWN GI Group of the French Anti-Cancer Centers
Jul 24, 2010·AJR. American Journal of Roentgenology·Mizuki NishinoAnnick D Van den Abbeele
Aug 25, 2010·Oncology·Mark F KozloffAxel Grothey
May 17, 2011·Lancet·Matthew T SeymourUNKNOWN National Cancer Research Institute Colorectal Cancer Clinical Studies Group
Jun 16, 2011·British Journal of Cancer·J CassidyL Saltz
Jul 17, 2012·Acta Oncologica·Sabine VenderboschMiriam Koopman
Nov 22, 2012·The Lancet Oncology·Jaafar BennounaUNKNOWN ML18147 Study Investigators
Nov 15, 2013·The Lancet Oncology·Yasuhide YamadaKenichi Sugihara
Mar 22, 2014·Molecular and Clinical Oncology·Yasutake UchimaKazuhiro Takeuchi
Apr 24, 2014·BMC Cancer·Lambros VamvakasJohn Souglakos
Aug 5, 2014·The Lancet Oncology·Volker HeinemannSebastian Stintzing
Citations
Aug 22, 2017·Cancer Chemotherapy and Pharmacology·Katsuki DannoUNKNOWN Colorectal Cancer Treatment Group (MCSGO)
Aug 15, 2017·Hospital Pharmacy·Meghan J GarrettDominic A Solimando
May 17, 2018·ESMO Open·Richard M GoldbergDaniele Santini
Sep 1, 2017·Expert Opinion on Drug Safety·Marta Pérez-De-LisManuel Ramos-Casals
May 11, 2018·The Tohoku Journal of Experimental Medicine·Shunsuke KatoChikashi Ishioka
May 8, 2019·International Journal of Clinical Oncology·Shun SasakiYoshihiko Maehara
Jul 25, 2019·International Journal of Clinical Oncology·Kosuke HiroseMasaki Mori
Mar 13, 2021·American Journal of Clinical Oncology·Edward AlabrabaUNKNOWN Nottingham HPB Surgery Group